Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
96 participants
INTERVENTIONAL
2025-03-20
2036-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
NCT02034110
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
NCT05868629
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
NCT01902173
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
NCT02974803
Special Drug Use-results Surveillance of Tafinlar/Mekinist
NCT06262919
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
treatment according to genetic alterations
treatment according to genetic alterations
Imatinib
imatinib treatment based on molecular alterations
Trametinib
According to biomarkers
Dabrafenib
According to biomarkers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imatinib
imatinib treatment based on molecular alterations
Trametinib
According to biomarkers
Dabrafenib
According to biomarkers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* identified biomarker,
* reasonable biochemistry
Exclusion Criteria
* serious other diseases
16 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helse Stavanger HF
OTHER_GOV
University Hospital of North Norway
OTHER
StOlavs Hospital
UNKNOWN
Nordlandssykehuset HF
OTHER
Helse Nord-Trøndelag HF
OTHER
Sorlandet Hospital HF
OTHER_GOV
Møre og Romsdal Hospital Trust
OTHER
The Hospital of Vestfold
OTHER
Helse Fonna
OTHER
Haukeland University Hospital
OTHER
Sykehuset Ostfold
OTHER
Helse Forde
OTHER
Sykehuset Innlandet HF
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Åslaug Helland
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sigbjørn Smeland, MD PhD
Role: STUDY_CHAIR
Oslo University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo University Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MATRIX-Rare
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.